Thiazoles

Knopp Biosciences Reports Positive Results From the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021

Retrieved on: 
Monday, May 17, 2021
Research, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Drugs, Branches of biology, Medical specialties, Dexpramipexole, Thiazoles, Asthma, Eosinophil, Paracetamol, Reslizumab

b'Knopp Biosciences LLC today announced detailed results of its positive Phase 2 dose-ranging EXHALE trial of the novel oral eosinophil-lowering drug dexpramipexole in patients with moderate-to-severe asthma.

Key Points: 
  • b'Knopp Biosciences LLC today announced detailed results of its positive Phase 2 dose-ranging EXHALE trial of the novel oral eosinophil-lowering drug dexpramipexole in patients with moderate-to-severe asthma.
  • The data were presented in a virtual poster session at the ATS 2021 International Conference.\nThe EXHALE trial was a randomized, double-blind, placebo-controlled study of dexpramipexole in patients with moderate-to-severe asthma and blood absolute eosinophil count (AEC) \xe2\x89\xa5300/\xc2\xb5L.
  • Dexpramipexole study drug at oral doses of 75 mg/day, 150 mg/day, or 300 mg/day was added to standard of care.
  • Eosinophils, a type of white-blood cell, are validated as a therapeutic target in asthma as evidenced by the regulatory approval of multiple eosinophil-lowering biologics.

Knopp Biosciences to Present Details of Positive Results From the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021

Retrieved on: 
Thursday, May 13, 2021
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Branches of biology, Medical specialties, Clinical medicine, Dexpramipexole, Thiazoles, Eosinophil, Asthma, Hypereosinophilic syndrome

Knopp\xe2\x80\x99s clinical-stage oral small molecule, dexpramipexole, is in Phase 2 clinical trials in moderate-to-severe eosinophilic asthma.

Key Points: 
  • Knopp\xe2\x80\x99s clinical-stage oral small molecule, dexpramipexole, is in Phase 2 clinical trials in moderate-to-severe eosinophilic asthma.
  • Knopp\xe2\x80\x99s preclinical Kv7 platform is directed to small-molecule treatments for developmental and epileptic encephalopathies, other epilepsies, neuropathic pain, and tinnitus.
  • Please visit www.knoppbio.com.\nDexpramipexole, a selective inhibitor of eosinophil maturation, is an oral small molecule drug in development by Knopp for asthma and other eosinophil-associated diseases.
  • In hypereosinophilic syndrome, dexpramipexole has previously been shown in a Phase 2 trial to significantly reduce requirements for oral corticosteroids and in a subset of patients to produce durable disease remission.

Front Line COVID-19 Critical Care Alliance Releases Updated Protocols for More Effective Treatment of COVID-19

Retrieved on: 
Thursday, April 29, 2021
Organic compounds, Chemical compounds, Chemistry, Coenzymes, Thiazoles, Biomolecules, Organic acids, Antioxidants, Paul E. Marik, Heparin, Vitamin C, Thiamine

The name MATH+ coming from the medications used in the protocol; Methylprednisolone, Ascorbic Acid, Thiamine, Heparin and (+) ivermectin, atorvastatin, zinc, vitamin-d, famotidine and melatonin.

Key Points: 
  • The name MATH+ coming from the medications used in the protocol; Methylprednisolone, Ascorbic Acid, Thiamine, Heparin and (+) ivermectin, atorvastatin, zinc, vitamin-d, famotidine and melatonin.
  • The protocol provides guidance for the treatment of the pulmonary phase of this disease with the goal of reducing hospital mortality.
  • said Paul E. Marik, M.D., FCCM, FCCP, founding member of the FLCCC and Chief, Pulmonary and Critical Care Medicine at Eastern Virginia Medical School.
  • Their MATH+ Hospital Treatment Protocol introduced in March 2020, has saved thousands of patients who were critically ill with COVID-19.

Health Canada releases decisions on neonicotinoid pesticides for impact on aquatic insects

Retrieved on: 
Wednesday, March 31, 2021
Insecticides, Neonicotinoids, Chemical compounds, Chloroarenes, Thiazoles, Organic compounds, Clothianidin, Chemical substances, Beekeeping, Pesticide toxicity to bees, Thiamethoxam, Pest Management Regulatory Agency

OTTAWA, ON, March 31, 2021 /CNW/ -Today,following a special review that included broad public consultation and science-based assessments, Health Canada released its decisions on the risks to aquatic insects from two neonicotinoid pesticides: clothianidin and thiamethoxam .

Key Points: 
  • OTTAWA, ON, March 31, 2021 /CNW/ -Today,following a special review that included broad public consultation and science-based assessments, Health Canada released its decisions on the risks to aquatic insects from two neonicotinoid pesticides: clothianidin and thiamethoxam .
  • To protect aquatic insects, Health Canada will be updating the use of some uses of clothianidin and thiamethoxam, and introducing additional mitigation measures and restrictions on some of the uses that remain registered.
  • When used according to new mitigation measures, clothianidin and thiamethoxam will not pose additional risks to aquatic insects.
  • Health Canada's Pest Management Regulatory Agency is responsible for pesticide regulation in Canada.

Allarity Therapeutics Initiates Phase 2 Trial of IXEMPRA® in Europe for the Treatment of Metastatic Breast Cancer

Retrieved on: 
Thursday, March 4, 2021
Chemical compounds, Breast cancer, Lactams, Cancer treatments, Bristol-Myers Squibb, Epoxides, Ixabepilone, Thiazoles, Metastatic breast cancer, CDK inhibitor, Pelareorep

Hrsholm, Denmark (4 March 2021) Allarity Therapeutics A/S (Allarity or the Company) today announced that it has enrolled the first patient in its European Phase 2 clinical trial of IXEMPRA (ixabepilone) for the treatment of metastatic breast cancer.

Key Points: 
  • Hrsholm, Denmark (4 March 2021) Allarity Therapeutics A/S (Allarity or the Company) today announced that it has enrolled the first patient in its European Phase 2 clinical trial of IXEMPRA (ixabepilone) for the treatment of metastatic breast cancer.
  • The U.S. Food and Drug Administration (FDA) approved IXEMPRA, a microtubulin inhibitor, in 2007 for the treatment of metastatic breast cancer.
  • We are pleased to announce the enrollment of the first patient in our DRP-guided Phase 2 clinical trial for IXEMPRA, one of our prioritized pipeline programs.
  • Allarity is currently conducting a DRP-guided Phase 2 clinical trial to evaluate IXEMPRA for the treatment of third-line metastatic breast cancer, with numerous trial sites planned in Europe, including Belgium, England, Denmark, Finland, Poland and Germany.

Worldwide Cephalosporin Industry to 2026 - by Generation, Route of Administration, Application and Region

Retrieved on: 
Wednesday, February 24, 2021
Cephalosporin, Enones, Antibiotic, Thiazoles, Drugs, Health, Medicine

The global cephalosporin market reached a value of US$ 17.46 Billion in 2020.

Key Points: 
  • The global cephalosporin market reached a value of US$ 17.46 Billion in 2020.
  • There are currently five generations of cephalosporin drugs available in the market with a slight difference in their antibacterial spectrum.
  • These medicines are also differentiated on the basis their administration, excretion, absorption and the duration of the effect of cephalosporin on the body.
  • Looking forward, the publisher expects the global cephalosporin market to exhibit moderate growth during the next five years.

Basilea reports strong 2020 financial results and significant progress in the clinical pipeline of its oncology assets

Retrieved on: 
Tuesday, February 16, 2021
Tertiary alcohols, Astellas Pharma, Isavuconazonium, Nitriles, Prodrugs, Thiazoles, Chemistry

The achievements in 2020 include launches in key markets in Asia Pacific and the approval in Russia.

Key Points: 
  • The achievements in 2020 include launches in key markets in Asia Pacific and the approval in Russia.
  • We therefore remain confident that our partners will have launched Cresemba in 60 countries by the end of 2021.
  • In 2020, our partner CR Gosun obtained regulatory approval for Zevtera in China, which triggered a milestone payment of CHF 3 million to Basilea.
  • We are therefore looking forward to interim results from this second cohort of FIDES-01, which are expected for H1 2021.

Knopp Biosciences Announces Positive Top-Line Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma

Retrieved on: 
Thursday, January 14, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical trials, Medical specialties, Clinical medicine, Respiratory therapy, Medicine, Dexpramipexole, Thiazoles, Asthma, Monoclonal antibodies, Reslizumab

Knopp Biosciences LLC today announced positive top-line results in a Phase 2 dose-ranging trial of the novel oral drug dexpramipexole in patients with moderate-to-severe eosinophilic asthma.

Key Points: 
  • Knopp Biosciences LLC today announced positive top-line results in a Phase 2 dose-ranging trial of the novel oral drug dexpramipexole in patients with moderate-to-severe eosinophilic asthma.
  • In the EXHALE trial, eosinophil depletion in blood by oral dexpramipexole correlated with clinically important improvement in lung function as measured by pre-bronchodilator FEV1.
  • These Phase 2 results strongly support the continued development of dexpramipexole as a potential first-in-class oral agent for the treatment of eosinophilic asthma, said Michael Bozik, M.D., President and CEO of Knopp.
  • Knopps clinical-stage oral small molecule, dexpramipexole, is in Phase 2 clinical trials in moderate-to-severe eosinophilic asthma.

Dr. Reddy's Laboratories announces the launch of Febuxostat Tablets in the U.S. Market

Retrieved on: 
Monday, January 11, 2021
Biotechnology, FDA, Pharmaceutical, Health, Companies, Chemical compounds, Pharmaceutical companies, Febuxostat, Nitriles, Thiazoles, NIFTY 50, Dr. Reddy's Laboratories, IQVIA, Medication

Consider the risks and benefits of Febuxostat when deciding to prescribe or continue patients on Febuxostat.

Key Points: 
  • Consider the risks and benefits of Febuxostat when deciding to prescribe or continue patients on Febuxostat.
  • *IQVIA Retail and Non-Retail MAT October 2020.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Basilea’s partner Asahi Kasei Pharma completes patient enrolment in phase 3 study with antifungal isavuconazole (Cresemba®) in Japan

Retrieved on: 
Thursday, January 7, 2021
Companies, Astellas Pharma, Isavuconazonium, Nitriles, Prodrugs, Thiazoles, Basilea Pharmaceutica, Kasei, Asahi, Chemistry

Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that patient enrolment has been completed in the phase 3 study with the antifungal isavuconazole (Cresemba), which is conducted in Japan by Basileas partner Asahi Kasei Pharma Corporation (Asahi Kasei Pharma).

Key Points: 
  • Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that patient enrolment has been completed in the phase 3 study with the antifungal isavuconazole (Cresemba), which is conducted in Japan by Basileas partner Asahi Kasei Pharma Corporation (Asahi Kasei Pharma).
  • Our partner Asahi Kasei Pharma expects to obtain study results in the second half of 2021, which will be the next major milestone for potentially making Cresemba available for patients in Japan.
  • The partnership between Basilea and Asahi Kasei Pharma was established in September 2016.
  • Under the terms of the agreement, Asahi Kasei Pharma was granted an exclusive license to develop and commercialize isavuconazole in Japan.